CD274 and non-small cell lung carcinoma: The PEARLS/KEYNOTE-091 trial evaluated one year of adjuvant pembrolizumab compared with placebo in patients with any PD-L1 expression and IB (T ≥ 4 cm) to IIIA NSCLC (per AJCC 7th edition) following surgical resection and chemotherapy (which was strongly recommended for stage II and II and considered for stage IB disease, but not required).